During the corresponding time, Ligand Pharmaceuticals Incorporated recorded a revenue increase by 33.73 % year on year, sequentially revenue grew by 23.14 %. While revenue at the Ligand Pharmaceuticals Incorporated's corporate clients
Sparsentan: A Breakthrough in IgA Nephropathy Treatment and its Impact on Ligand Pharmaceuticals The recent full FDA approval of FILSPARI (sparsentan) marks a significant advancement in the treatment of Immunoglobulin A Nephropathy (IgAN). Travere Therapeutics, in partnership with Ligand Pharmaceuticals, has developed sparsentan, the first non-immunosuppressive therapy that effectively slows kidney function decline in adults with primary IgAN. This approval not only presents a promising treatment option for patients but also signifies a noteworthy milestone for Ligand Pharmaceuticals. In this article, we explore the key facts surrounding this development and assess its potential impact on Ligand Pharmaceut...
: The approval of Ohtuvayre (ensifentrine) by the U.S. Food and Drug Administration (FDA) marks pivotal progress in the treatment paradigm of chronic obstructive pulmonary disease (COPD). Developed by Verona Pharma plc in collaboration with Ligand Pharmaceuticals Incorporated, Ohtuvayre stands as the first inhaled drug with a novel mechanism of action for the maintenance treatment of COPD in over 20 years. This article discusses the significance of this approval, the innovative mechanism of Ohtuvayre, its clinical efficacy, safety profile, and its potential impact on patient outcomes and future COPD treatment strategies. Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mo...
Sources:
Ligand Pharmaceuticals Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ligand Pharmaceuticals Incorporated’s corporate clients.
For your research, we’ve provided 9 tables on Ligand Pharmaceuticals Incorporated corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
110.36 %